+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cancer Supportive Care - Global Strategic Business Report

  • PDF Icon

    Report

  • 262 Pages
  • October 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5139745
The global market for Cancer Supportive Care was estimated at US$27.1 Billion in 2023 and is projected to reach US$31.4 Billion by 2030, growing at a CAGR of 2.1% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Cancer Supportive Care Market - Key Trends and Drivers Summarized

Why Is Cancer Supportive Care Essential in Modern Oncology?

Cancer supportive care has become a fundamental aspect of modern oncology, playing a crucial role in enhancing the quality of life for patients undergoing aggressive cancer treatments such as chemotherapy, radiation therapy, and surgical interventions. These treatments, while targeting the malignancy effectively, often come with severe side effects, including pain, nausea, fatigue, and immune suppression, which can drastically affect a patient's physical and emotional well-being. Supportive care aims to alleviate these adverse effects through a wide range of therapies, medications, and psychological interventions. In recent years, this field has expanded significantly, encompassing not just traditional pain management and anti-nausea treatments but also interventions for anemia, infections, and psychological distress. Holistic approaches that integrate physical symptom management with emotional support have proven to be essential in helping patients adhere to their treatment plans. Moreover, cancer supportive care helps improve the overall quality of life, ensuring that patients can endure their treatment with dignity and strength, making it a critical component of comprehensive cancer care.

How Are Technological Innovations Transforming Cancer Supportive Care?

Technological advancements have revolutionized cancer supportive care, offering more precise, effective, and patient-friendly solutions to manage the side effects of cancer treatments. One of the most notable breakthroughs is the development of targeted and long-acting medications, such as advanced antiemetic drugs that provide prolonged relief from nausea or biologics that address chemotherapy-induced anemia by stimulating red blood cell production. Digital health technologies are playing an increasingly significant role, with mobile health applications, telemedicine platforms, and wearable devices enabling patients to receive real-time support and monitor their health status from the comfort of their homes. These tools allow patients to track symptoms, receive medication reminders, and stay in constant communication with their healthcare providers, ensuring timely interventions for any emerging issues. In addition, wearable technology, which monitors vital signs like blood pressure and heart rate, can detect early signs of complications such as infection or dehydration, allowing for prompt treatment and reducing the need for hospitalization. Innovations in immunotherapies and personalized medicine have also expanded the need for specialized supportive care, as these therapies often come with unique side effects that require targeted management. Collectively, these technological advances are making cancer supportive care more precise, accessible, and tailored to individual patient needs, leading to better treatment adherence and improved outcomes.

What Are the Key Trends and Challenges in Cancer Supportive Care?

Several significant trends are reshaping the cancer supportive care market, reflecting a shift toward more personalized, patient-centered care. One of the key trends is the growing use of individualized supportive care plans, which take into account a patient's specific cancer type, treatment regimen, and personal health characteristics. This personalized approach is part of the broader movement toward precision medicine in oncology, where treatments are tailored to the unique needs of each patient. Another important trend is the increasing focus on home-based care. With the advent of telemedicine and digital health platforms, patients can now receive supportive care from their homes, reducing the need for frequent hospital visits and improving overall convenience. The rise of remote monitoring and virtual consultations has made it possible for healthcare providers to manage side effects and adjust treatments in real-time, further enhancing patient comfort and safety. However, the field faces notable challenges, including the high cost of supportive care treatments, particularly for newer biologics and specialized interventions. There are also disparities in access to these services, especially in low-resource settings, where patients may not have access to the full range of supportive care options. Managing the complex side effects of modern treatments like immunotherapy also remains a challenge, as these therapies often introduce new and unpredictable complications. Despite these hurdles, the shift toward integrated, holistic care models continues to drive innovation in cancer supportive care, offering patients more comprehensive and effective management of their symptoms.

What's Driving the Growth in the Cancer Supportive Care Market?

The growth in the cancer supportive care market is driven by several factors, including the rising global incidence of cancer, advancements in cancer treatments, and the increasing focus on improving patient quality of life. One of the most significant drivers is the global rise in cancer cases, fueled by aging populations, lifestyle changes, and environmental factors. As more patients undergo aggressive treatments like chemotherapy, radiation, and immunotherapy, the need for supportive care to manage the associated side effects has grown substantially. Innovations in cancer treatments, particularly the advent of personalized medicine and immunotherapies, have introduced new challenges, as these therapies often come with unique side effects that require specialized supportive care interventions. Another major factor driving growth is the increasing recognition of the importance of palliative care and quality of life in cancer treatment. Healthcare providers and policymakers are placing a greater emphasis on ensuring that patients not only survive their cancer treatment but also maintain their well-being throughout the process. In addition, government initiatives and healthcare policies that promote access to comprehensive cancer care have boosted investments in supportive care services and infrastructure. Digital health technologies, including telemedicine, remote patient monitoring, and home-based care options, are also contributing to the expansion of the market by making supportive care more accessible, particularly in rural and underserved areas. These factors, combined with the growing focus on patient-centered care, continue to propel the cancer supportive care market forward, offering more effective and holistic solutions to manage the complex needs of cancer patients.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Opioids Therapeutic Class segment, which is expected to reach US$11.1 Billion by 2030 with a CAGR of a 2.3%. The G-CSFs Therapeutic Class segment is also set to grow at 1.5% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, which was estimated at $7.3 Billion in 2023, and China, forecasted to grow at an impressive 1.8% CAGR to reach $4.9 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Cancer Supportive Care Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Cancer Supportive Care Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Cancer Supportive Care Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Amgen, Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 16 Featured):

  • Amgen, Inc.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Helsinn Healthcare SA
  • Heron Therapeutics, Inc.
  • Johnson & Johnson
  • Kyowa Hakko Kirin Co., Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Tesaro, Inc.
  • Teva Pharmaceutical Industries Ltd.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Cancer Supportive Care - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Cancer Incidence Globally Spurs Growth in Demand for Cancer Supportive Care Solutions
  • Advances in Chemotherapy and Radiation Treatments Throw the Spotlight on Supportive Care Needs
  • Focus on Patient-Centered Care Expands Addressable Market Opportunity for Supportive Therapies
  • Growth in Palliative Care Programs Propels Demand for Cancer Supportive Care Medications
  • Increasing Focus on Nutritional Support and Supplements Sustains Growth in Cancer Supportive Care Market
  • Technological Innovations in Digital Health Generate New Opportunities for Cancer Supportive Care Monitoring
  • Growing Awareness About Managing Treatment-Related Side Effects Propels Market Expansion
  • Rising Adoption of Home Healthcare Expands Market Potential for Cancer Supportive Care Services
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Cancer Supportive Care Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Cancer Supportive Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 3: World Historic Review for Cancer Supportive Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 4: World 16-Year Perspective for Cancer Supportive Care by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Opioids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 6: World Historic Review for Opioids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 7: World 16-Year Perspective for Opioids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for G-CSFs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 9: World Historic Review for G-CSFs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 10: World 16-Year Perspective for G-CSFs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 12: World Historic Review for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 13: World 16-Year Perspective for NSAIDs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Bisphosphonates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 15: World Historic Review for Bisphosphonates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 16: World 16-Year Perspective for Bisphosphonates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for ESAs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 18: World Historic Review for ESAs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 19: World 16-Year Perspective for ESAs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 20: World Recent Past, Current & Future Analysis for Antiemetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 21: World Historic Review for Antiemetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 22: World 16-Year Perspective for Antiemetics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Cancer Supportive Care Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 23: USA Recent Past, Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 24: USA Historic Review for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 25: USA 16-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics for the Years 2014, 2024 & 2030
CANADA
  • Table 26: Canada Recent Past, Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 27: Canada Historic Review for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 28: Canada 16-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics for the Years 2014, 2024 & 2030
JAPAN
  • Cancer Supportive Care Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 29: Japan Recent Past, Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 30: Japan Historic Review for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 31: Japan 16-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics for the Years 2014, 2024 & 2030
CHINA
  • Cancer Supportive Care Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 32: China Recent Past, Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 33: China Historic Review for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 34: China 16-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics for the Years 2014, 2024 & 2030
EUROPE
  • Cancer Supportive Care Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 35: Europe Recent Past, Current & Future Analysis for Cancer Supportive Care by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 36: Europe Historic Review for Cancer Supportive Care by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 37: Europe 16-Year Perspective for Cancer Supportive Care by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • Table 38: Europe Recent Past, Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 39: Europe Historic Review for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 40: Europe 16-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics for the Years 2014, 2024 & 2030
FRANCE
  • Cancer Supportive Care Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 41: France Recent Past, Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 42: France Historic Review for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 43: France 16-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics for the Years 2014, 2024 & 2030
GERMANY
  • Cancer Supportive Care Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 44: Germany Recent Past, Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 45: Germany Historic Review for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 46: Germany 16-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics for the Years 2014, 2024 & 2030
ITALY
  • Table 47: Italy Recent Past, Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 48: Italy Historic Review for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 49: Italy 16-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Cancer Supportive Care Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 50: UK Recent Past, Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 51: UK Historic Review for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 52: UK 16-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics for the Years 2014, 2024 & 2030
REST OF EUROPE
  • Table 53: Rest of Europe Recent Past, Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 54: Rest of Europe Historic Review for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 55: Rest of Europe 16-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Cancer Supportive Care Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 56: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 57: Asia-Pacific Historic Review for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 58: Asia-Pacific 16-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics for the Years 2014, 2024 & 2030
REST OF WORLD
  • Table 59: Rest of World Recent Past, Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 60: Rest of World Historic Review for Cancer Supportive Care by Therapeutic Class - Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 61: Rest of World 16-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for Opioids, G-CSFs, NSAIDs, Bisphosphonates, ESAs and Antiemetics for the Years 2014, 2024 & 2030
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Amgen, Inc.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Helsinn Healthcare SA
  • Heron Therapeutics, Inc.
  • Johnson & Johnson
  • Kyowa Hakko Kirin Co., Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Tesaro, Inc.
  • Teva Pharmaceutical Industries Ltd.

Table Information